To monitor safety and assess bioequivalence of Leuprolide Acetate 7.5 mg Depot suspension of Sun Pharmaceutical Industries Limited,India and Lupron Depot 7.5 mg depot suspension of TAP Pharmaceutical Inc., USA under fasting conditions in prostatic carcinoma patients undergoing initial therapy.

Completed

• Conditions: Cancer(Prostatic carcinoma patients, undergoing initial therapy)

• Registration Number: CTRI/2012/02/002436
• Lead Sponsor: Sun Pharmaceutical Industries Ltd

Brief Summary

This study is a randomized, multi center, open label, two treatment, two period, two sequence, single dose, crossover study for monitoring the safety of the subjects participating in the study and to assess the bioequivalence of Leuprolide Acetate 7.5 mg Depot suspension of Sun Pharmaceutical Industries Limited, India and Lupron Depot (Leuprolide Acetate) 7.5 mg depot Suspension of TAP Pharmaceutical Inc., Lake Forest, IL 60045, USA, under fasting conditions in 60 Prostatic carcinoma patients undergoing initial therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01-03
• Last Update Posted: 2013-12-02

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

• Volunteers meeting all of the following criteria will be considered for enrollment in the study: i.
• Availability of volunteer for the entire study period and willingness to adhere to protocol requirements.
• Prostatic carcinoma patients undergoing initial therapy, at least 18-years of age or older, subject’s body mass index (BMI) must be within 18.5 – 30.0 (Kg/m2).
• Subjects who have no evidence of underlying disease (Except Prostatic carcinoma) during screening medical history and whose physical examination is performed within 28 days prior to commencement of the study.
• Patients whose life expectancy of greater than or equal to 6 months.
• Subjects whose screening laboratory values are within normal limits or considered by the Investigator/sub-Investigator to be of no clinical significance.

Exclusion Criteria

• History or presence of significant: i.
• Allergy or Significant history of hypersensitivity to Leuprolide and/or any of the excipients in Leuprolide depot and GnRH, GnRH agonist analogs.
• Evidence of severe renal, hepatic, cardiovascular or psychiatric illness.
• Alcohol dependence, alcohol abuse or drug abuse or addiction with any recreational drug within past one year.
• Smoking or consumption of tobacco products.
• Difficulty in coming for follow up.
• Clinically significant illness (except defined in section 6.4 ii) within 4 weeks before the start of the study vii.
• Positive result to HIV, HCV, RPR and HBsAg. viii.
• Abnormal 12 lead ECG, X-ray.
• Donation of 350 mL or more of blood in the previous 90 days before day 1 of this study 3.
• Participation in another clinical trial within the preceding 90 days of study starts.
• Subjects who have: i.
• Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg ii.
• Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg. Minor deviations (2-4mm Hg) at check-in may be acceptable at the discretion of the Investigator.
• Pulse rate below 60/min.
• or above 100/min.

Study & Design

• Study Type: BA/BE
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) To characterize the rate and extent of bioavailability of the test products in comparison with the reference product after single dose administration under fasting conditions,	Pre-dose blood sample: 10 ml will be collected within a period of 15 minute before dosing. | Post dose sample :0.25, 0.50, 0.75, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.33, 4.67, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 48.0, 72.0, 168.0, 360.0, 504.0 and 672.0 hours post dosing (1 x 3 ml each) in plain vacutainers in each period. | Note:The 672.00hr post dose sampling for period I will be consider as the predose blood samples for period.
2) Monitor the safety of the subjects participating in the study and the tolerability of the test products in comparison with the reference considering adverse events.	Pre-dose blood sample: 10 ml will be collected within a period of 15 minute before dosing. | Post dose sample :0.25, 0.50, 0.75, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.33, 4.67, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 48.0, 72.0, 168.0, 360.0, 504.0 and 672.0 hours post dosing (1 x 3 ml each) in plain vacutainers in each period. | Note:The 672.00hr post dose sampling for period I will be consider as the predose blood samples for period.

Secondary Outcome Measures

Name	Time	Method
NA	NA

Trial Locations

Locations (11)

Bodyline Hospital; 🇮🇳 Ahmadabad, GUJARAT, India

Dr. G. Viswanathan Speciality Hospital; 🇮🇳 Tiruchirappalli, TAMIL NADU, India

Dr. Kamakshi Memorial Hospital; 🇮🇳 Chennai, TAMIL NADU, India

Julian Nursing Home; 🇮🇳 Chennai, TAMIL NADU, India

Kovai Medical Center and Hospital Ltd; 🇮🇳 Coimbatore, TAMIL NADU, India

MANU HOSPITAL AND RESEARCH CENTER; 🇮🇳 Jaipur, RAJASTHAN, India

Melmaruvathur Adhiparasakthi Institute of Medical Science and Research; 🇮🇳 Kancheepuram, TAMIL NADU, India

NRR Hospital; 🇮🇳 Bangalore, KARNATAKA, India

Rajiv Gandhi Cancer Institute & Research centre; 🇮🇳 Delhi, DELHI, India

RATKAL SPECIALITY HOSPITALS (P) LTD; 🇮🇳 Bangalore, KARNATAKA, India

Scroll for more (1 remaining)

Bodyline Hospital

🇮🇳Ahmadabad, GUJARAT, India

Dr Shailesh Shah

Principal investigator

919824035673

kidneyline@gmail.com